Researchers argue that deploying antibody tests widely in communities could ultimately help ease restrictions put in place to slow the spread of the novel SARS-CoV-2 coronavirus.
While PCR tests are currently being used to identify people who are infected with the novel coronavirus, antibody or serology tests look for antibodies- proteins made by the body to combat infection. Antibody tests are slower than PCR tests and should not be used to diagnose the virus, but they may help identify people who have recovered from Covid-19 but did not show significant symptoms.
An official of the Communicable Disease Control (CDC) unit of the Directorate General of Health Services (DGHS), seeking anonymity, said the tests would provide a better understanding of how many people have recovered from Covid-19.
The antibody tests could also play an additional role — confirming who qualifies to donate convalescent blood plasma to treat Covid-19 patients. Bangladesh recently began plasma therapy, the official added.
NIPSOM professor Dr Be-Nazir Ahmed said antibody tests would enable specialists to more accurately estimate the dynamics and rate of the virus’ spread.
This would help them design better strategies to safeguard communities and possibly also allow for more freedom of movement, he added.
According to the US Centers for Disease Control and Prevention (US CDC), antibody tests are important for identifying previous infections in people who had few or no symptoms. However, it is yet to be determined whether antibodies provide immunity to future Covid-19 infection, or for how long if it does.
The US CDC is currently in the process of evaluating the performance of commercial antibody tests, with the aim of estimating the percentage of people previously infected with Covid-19 in the US. The US CDC’s serologic test has a specificity of greater than 99% and a sensitivity of 96% based on initial performance evaluations, and can identify patients who were infected 1-3 weeks before testing.
The EU and the Food and Drug Administration (FDA) of the US, both recently validated an antibody test developed by the healthcare and medical device company, Abbott Laboratories. Abbott claims their test has 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began, according to international media reports.
"Antibody testing has the potential to unlock a lot of unknowns about this novel virus. Having tests that can work in different healthcare settings is critical to our understanding of the virus and to helping give healthcare providers answers they need about their patients," said John Hackett, divisional vice president of Applied Research and Technology, Diagnostics of Abbott, on their website.